Xiaowen Zhong

Xiaowen Zhong

Auto-generated profile, based on publicly available information

Xiaowen Zhong

Department of Pediatrics, O’Neal Comprehensive Cancer Center, Heersink School of Medicine, University of Alabama at Birmingham (UAB) , Birmingham, Alabama

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2025 in Science Advances
Verified
Journal Article
Open access
FCFangbing Chen
Fangbing Chen
XLXi Liu
Xi Liu
XZXiaowen Zhong
Xiaowen Zhong
XCXiaoqing Chen
Xiaoqing Chen
ENEva Nicholson
Eva Nicholson
RLRichard Lu
Richard Lu
In vivo conversion of nonneuronal cells into neurons is a proposed strategy to replace neurons lost to CNS injury or disease. Glia-to-neuron trans-differentiation by viral vector–mediated GFAP mini-promoter–driven NeuroD1 remains hotly debated. Developing inducible, lineage-traceable transgenic mice, we find that astrocyte-to-neuron conversion is restricted to a specific time window within the lesion core of injured spinal cord and brain. Spatiotemporal lineage-mapping combined with single-cell transcriptomics reveals that ectopic NeuroD1 induces astrocyte-to-neuron conversion specifically in lesion cores via transit-amplifying OLIG2 + progenitors during early injury phase, but not in late phases or in nonreactive astrocytes. Neither a loss-of-function NeuroD1 mutant nor stemness-reprogramming factor SOX2 induces astrocyte-to-neuron conversion. However, contrary to previous reports, the neuronal-like cells generated by NeuroD1 lack mature neuroelectrical properties, limiting their functional integration into neural circuits. Together, our findings establish a spatiotemporal framework for NeuroD1-driven glia-to-neuron conversion, revealing a mechanistic shift from direct astrocyte conversion toward transit-amplifying intermediates and highlighting the functional immaturity of NeuroD1-converted neurons.

31 August 2026 in Neuro-Oncology
Verified
Journal Article
Closed access
BDBing Deng
Bing Deng
XZXiaowen Zhong
Xiaowen Zhong
DXDazhuan Xin
Dazhuan Xin
XHXiao Huang
Xiao Huang
USUpendra K Soni
Upendra K Soni
RLRichard Lu
Richard Lu
Background: Diffuse middle glioma (DMG or DIPG) is a fatal pediatric brain tumor. Although chimeric antigen receptor (CAR) T-cell therapy shows promise, clinical outcomes remain inconsistent due to premature exhaustion, underscoring a critical need to improve CAR-T persistence. A major barrier to CAR-T efficacy is antigen-independent tonic signaling, yet the extent to which tonic signaling shapes CAR-T durability and clinical outcomes, particularly in DMG, remains incompletely defined. Methods: Using a clinically investigated B7-H3 MGA271-based CAR as a reference platform, we generated alternative B7-H3 CARs incorporating either a human codon-optimized 376.96 (B7H3.BC) or Hu8H9 scFv antigen-binding domain to systematically assess scFv-dependent effects on tonic signaling and therapeutic efficacy. CAR-T cells were evaluated using integrated in vitro and in vivo functional assays, alongside multi-omics profiling and computational modeling. We further derived a tonic signaling-associated gene signature and evaluated its predictive performance across independent clinical datasets. Results: B7H3.BC CAR-T cells exhibit markedly restrained tonic signaling compared with MGA271- and Hu8H9-based counterparts, accompanied by superior antitumor activity and enhanced persistence across patient-derived DMG cells. Integrated multi-omics and single-cell profiling further identified a tonic signaling-associated gene signature that outperforms conventional T-cell exhaustion signatures in predicting therapeutic efficacy across multiple clinical trials, including DMG and other tumors. Conclusions: Our findings establish that scFv-dependent modulation of tonic signaling critically governs CAR-T persistence and antitumor efficacy in DMG. By linking CAR design to transcriptional and epigenetic programs, our study provides a principle-based and predictive framework to inform rational CAR engineering and improve therapeutic outcomes.